Literature DB >> 29386869

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

Troy Kish.   

Abstract

Upcoming antibacterial agents in the pipeline appear promising, but it is difficult to predict their long-term durability. This article focuses on investigational agents that target resistant gram-negative organisms commonly found in the health care setting.

Year:  2018        PMID： 29386869      PMCID： PMC5768301     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  10 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  The ABCD's of β-lactamase nomenclature.

Authors:  Karen Bush
Journal:  J Infect Chemother       Date:  2013-07-05       Impact factor: 2.211

3.  Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.

Authors:  Joseph Solomkin; David Evans; Algirdas Slepavicius; Patrick Lee; Andrew Marsh; Larry Tsai; Joyce A Sutcliffe; Patrick Horn
Journal:  JAMA Surg       Date:  2017-03-01       Impact factor: 14.766

4.  In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Authors:  Douglas J Biedenbach; Krystyna Kazmierczak; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

5.  Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.

Authors:  Maria Del Carmen López-Diaz; Esther Culebras; Iciar Rodríguez-Avial; Esther Rios; José Manuel Viñuela-Prieto; Juan J Picazo; Carmen Rodríguez-Avial
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.

Authors:  Christopher Lucasti; Liviu Vasile; Dorel Sandesc; Donatas Venskutonis; Patrick McLeroth; Mallika Lala; Matthew L Rizk; Michelle L Brown; Maria C Losada; Alison Pedley; Nicholas A Kartsonis; Amanda Paschke
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Authors:  Helio S Sader; Rodrigo E Mendes; Michael A Pfaller; Dee Shortridge; Robert K Flamm; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Authors:  Matthew Sims; Valeri Mariyanovski; Patrick McLeroth; Wayne Akers; Yu-Chieh Lee; Michelle L Brown; Jiejun Du; Alison Pedley; Nicholas A Kartsonis; Amanda Paschke
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

9.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Authors:  Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191
  10 in total
  3 in total

1.  A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals.

Authors:  Laura Puzniak; Daryl D DePestel; Arjun Srinivasan; Gang Ye; John Murray; Sanjay Merchant; C Andrew DeRyke; Vikas Gupta
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting.

Authors:  Sabrina Morris; Elizabeth Cerceo
Journal:  Antibiotics (Basel)       Date:  2020-04-20

3.  In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.

Authors:  Yoshinori Yamano
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.